Trial Profile
Phase I clinical trial of MDCO 216 in healthy volunteers and patients with coronary artery disease.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs MDCO 216 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors The Medicines Company
- 17 Feb 2016 According to The Medicines Company media release, the company has announced positive results.
- 14 Dec 2015 Results published in The Medicine Company media release.
- 14 Dec 2015 Results published in the European Heart Journal - Cardiovascular Pharmacology, according to The Medicines Company media release.